Manufacturing of CAR-T cells using in-house vectors and the CliniMACS Prodigy

Probably not a substantial claim: may not pass S3 (load-bearing).

Critical process parameters are present at every step of the manufacturing process.

“Critical process parameters are present at every step of the manufacturing process.”

• cites [13]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim. May combine two claims.

This variation limits interlaboratory comparability and highlights the need for assay validation and harmonized reporting strategies.

“This variation limits interlaboratory comparability and highlights the need for assay validation and harmonized reporting strategies.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Transduction efficiency can vary considerably between patients and across manufacturing runs.

“Transduction efficiency can vary considerably between patients and across manufacturing runs.”

• cites [21]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S4 (based).

Automated closed systems such as the CliniMACS Prodigy can mitigate these challenges by reducing manual handling, standardizing procedures, and enhancing traceability.

“Automated closed systems such as the CliniMACS Prodigy can mitigate these challenges by reducing manual handling, standardizing procedures, and enhancing traceability.”

Probably not a substantial claim: may not pass S3 (load-bearing).

This difference in transduction efficiency frequently results from differences in starting-material composition, T-cell fitness and activation status, vector architecture, multiplicity of infection, culture density, or timing of vector addition.

“This difference frequently results from differences in starting-material composition, T-cell fitness and activation status, vector architecture, multiplicity of infection, culture density, or timing of vector addition.21”

• cites [21]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

Non-viral gene delivery approaches, including transposon systems, mRNA electroporation, and CRISPR-based engineering, are gaining attention as strategies to lower dependence on viral vectors, optimize regulatory pathways, and reduce manufacturing costs.

“In parallel, non-viral gene delivery approaches, including transposon systems such as Sleeping Beauty, mRNA electroporation, and CRISPR-based engineering, are gaining attention as strategies to lower dependence on viral vectors, optimize regulatory pathways, and reduce manufacturing costs.[34][35][36]”

• cites [34]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [35]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [36]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Serology or nucleic acid tests for infectious diseases are primarily based on institutional clinical protocols.

“It is evident from many publications that serology or nucleic acid tests for infectious diseases are primarily based on institutional clinical protocols.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Viability, lymphocyte markers, and sterility are key acceptance parameters.

“Viability, lymphocyte markers, and sterility are key acceptance parameters.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

The quality of the apheresis product strongly determines the final yield.

“The quality of the apheresis product strongly determines the final yield.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In-house vectors are commonly based on second- or third-generation lentiviral systems, which have been used for clinical-grade gene transfer because of their safety features, reduced risk, and suitability for stable transgene expression.

“In-house vectors may vary in design but are commonly based on second-or third-generation lentiviral systems, which have been used for clinical-grade gene transfer because of their safety features, reduced risk, and suitability for stable transgene expression.3,6”

• cites [3]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [6]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

Lentiviral vectors must undergo predefined QC testing, including functional titer, sterility, endotoxin, mycoplasma, and other quality parameters.

“Regardless of the supplier, lentiviral vectors must undergo predefined QC testing, including assessments of functional titer, sterility, endotoxin, mycoplasma, and other quality parameters.6”

• cites [6]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

CAR-T cell manufacturing requires complex, coordinated, time-sensitive steps involving apheresis, cell processing, QC laboratories, and clinical teams.

“Manufacturing CAR-T cells requires a series of complex, carefully coordinated, and time-sensitive steps involving apheresis, cell processing, quality control (QC) laboratories, and clinical teams.3”

• cites [3]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

The processed volume for leukapheresis usually ranges from 1 to 3 total blood volumes, with adjustments based on patient weight, peripheral blood counts, vascular access, and institutional protocols.

“The processed volume usually ranges from 1 to 3 total blood volumes, with adjustments based on patient weight, peripheral blood counts, vascular access, and institutional protocols.13”

• cites [13]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Point-of-care manufacturing models are gaining attention because they may shorten manufacturing time, reduce logistical complexity, and improve access for patients treated outside large industrial manufacturing networks.

“Point-of-care manufacturing models are also gaining attention because they may shorten manufacturing time, reduce logistical complexity, and improve access for patients treated outside large industrial manufacturing networks.33”

• cites [33]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Process validation includes equipment qualification and calibration, supplier qualification, validation of all analytical methods, cryopreservation procedures, and shipping conditions.

“This includes several aspects of the entire productive chain, such as equipment qualification and calibration, supplier qualification, validation of all analytical methods, cryopreservation procedures, and shipping conditions.”

• cites [31]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [32]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Regulatory rules relevant to CAR-T manufacturing in Brazil include Anvisa Resolution No. 505/2021 and No. 506/2021 for advanced therapy products, Resolution No. 836/2021 for GMP, and institutional biosafety requirements.

“Regulatory rules relevant to CAR-T manufacturing in Brazil include Agência Nacional de Vigilância Sanitária (Anvisa) Resolution No. 505/2021 and No. 506/2021 for advanced therapy products, Resolution No. 836/2021 for good manufacturing practices (GMP), and institutional biosafety requirements.[8][9][10][11]”

• cites [8]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [9]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [10]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [11]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

In academic or low-resource institutions, implementing robust QC can be very difficult, as it requires validated assays, trained personnel, qualified equipment, documented controls, and clear decision-making procedures for out-of-specification or atypical results.

“In this sense, in academic or low-resource institutions, implementing robust QC can be very difficult, as it requires validated assays, trained personnel, qualified equipment, documented controls, and clear decisionmaking procedures for out-of-specification or atypical results.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Products manufactured from heavily pretreated patients may present reduced cell proliferation, altered CD4/CD8 ratios, lower transduction efficiency, or increased expression of exhaustion markers.

“Products manufactured from heavily pretreated patients may present reduced cell proliferation, altered CD4/CD8 ratios, lower transduction efficiency, or increased expression of exhaustion markers.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Standard testing of starting material commonly involves measuring total nucleated cell count, CD3+ T-cell count, other lymphocyte markers, cell viability, and sterility.

“Standard testing commonly involves measuring total nucleated cell count, CD3+ T-cell count, other lymphocyte markers, cell viability, and sterility.”

• cites [16]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Classified as probably not a substantial claim.

Since CAR-T cells are autologous, maintaining chain-of-identity and chain-of-custody is essential at every step.

“Since CAR-T cells are autologous, maintaining the COI and the COC is essential at every step.17,18”

• cites [17]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [18]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Electronic records can reduce transcription errors and enable real-time review, but require validated systems, controlled access, and data integrity procedures.

“Electronic records are useful and can be used in order to reduce transcription errors and enable real-time review, but they require validated systems, controlled access, and data integrity procedures.27”

• cites [27]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

QA and IPC provide consistency, safety, traceability, and regulatory conformance throughout cell manufacturing.

“QA and IPC provide the consistency, safety, traceability, and regulatory conformance throughout cell manufacturing.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Release criteria may vary according to the manufacturing platform, clinical protocol, regulatory pathway, and whether the product is fresh or cryopreserved.

“Release criteria may vary according to the manufacturing platform, clinical protocol, regulatory pathway, and whether the product is fresh or cryopreserved.”

Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).

QC tests for CAR-T cell products must be rapid and reliable.

“QC tests for CAR-T cell products must be rapid and reliable.17”

• cites [17]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

The workflow underlying CAR-T cell manufacturing is fundamentally consistent across systems and laboratories in general terms, including the use of the CliniMACS Prodigy system.

“The workflow underlying CAR-T cell manufacturing is fundamentally consistent across systems and laboratories in general terms (Fig. 1), including the use of the CliniMACS Prodigy system.19”

• cites [19]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

Cell viability at product release typically requires values of at least 70%, determined by flow cytometry using viability dyes such as 7-AAD or equivalent reagents.

“Another feature is cell viability, assessed at the time of product release, and typically requires values of at least 70%, determined by flow cytometry using viability dyes such as 7-AAD or equivalent reagents.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

According to Brazilian resolutions, collected leukapheresis material should be stored at 2-8 °C, with transport maintained at 2-24 °C.

“According to Brazilian resolutions, 8,15 the collected material should be stored at 2-8 °C, with transport maintained at 2-24 °C.”

• cites [8]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [15]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Expansion failure or poor growth may occur because of heavily pretreated patients (inefficient washout), low CD3+ input, reduced cell viability, or high monocyte or granulocyte contamination in the starting material.

“Nevertheless, expansion failure or poor growth may occur, for example, because of heavily pretreated patients (inefficient washout), low CD3+ input, reduced cell viability, or high monocyte or granulocyte contamination in the starting material.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Cell culture expansion depends on factors including nutrient availability, cytokine supplementation, stable pH and gas exchange, control of cell density, and the proliferative capacity of the patient-derived T-cell population.

“Cell culture expansion depends on different factors, including nutrient availability, cytokine supplementation, stable pH and gas exchange, control of cell density, and the proliferative capacity of the patient-derived T-cell population.13”

• cites [13]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

One advantage of closed systems compared with conventional open systems is reduced operator-skill dependence and lower contamination risks, which lead to more consistent manufacturing outcomes.

“Also, one of the advantages of closed systems, compared with conventional open systems, is reduced operator-skill dependence and lower contamination risks, which lead to more consistent manufacturing outcomes.23”

• cites [23]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S3 (load-bearing).

The quality of the leukapheresis product is a critical determinant of manufacturing outcomes, as factors such as lymphopenia, elevated tumor burden, recent chemotherapy, ongoing infections, corticosteroid exposure, and other factors can affect CAR-T cell manufacturing.

“In parallel, the quality of the leukapheresis product is a critical determinant of manufacturing outcomes, as factors such as lymphopenia, elevated tumor burden, recent chemotherapy, ongoing infections, corticosteroid exposure, and other factors can affect CAR-T cell manufacturing.”

Probably not a substantial claim: may not pass S3 (load-bearing).

International guidelines such as FDA CMC guidance and FACT-JACIE Standards support harmonization of best practices.

“International guidelines, such as the U.S. Food and Drug Administration Chemistry, Manufacturing, and Control guidance for genemodified cellular therapies, and the Foundation for the Accreditation of Cellular Therapy-Joint Accreditation Committee International Society for Cell & Gene Therapy-Europe & European Society for Blood and Marrow Transplantation Standards further support the harmonization”

Probably not a substantial claim: may not pass S3 (load-bearing).

Potency testing remains one of the most challenging aspects of CAR-T-cell product release.

“Potency testing remains one of the most challenging aspects of CAR-T-cell product release.24”

• cites [24]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).

Traceability is essential due to the autologous nature of CAR-T products.

“Traceability is essential due to the autologous nature of CAR-T products.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Common deviations in CAR-T manufacturing include temperature excursions, delayed processing, labeling inconsistencies, incomplete documentation, reagent preparation errors, equipment alarms, flow occlusions, partial failures of automated steps, out-of-range cell densities, low transduction efficiencies, and microbial contamination.

“Common deviations include temperature excursions during transport or storage, delayed processing, labeling inconsistencies, incomplete documentation, reagent preparation errors, unexpected equipment alarms, flow occlusions, partial failures of automated steps, out-of-range cell densities, low transduction efficiencies, and microbial contamination.29”

• cites [29]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.